Patient-derived melanoma organoid models facilitate the assessment of immunotherapies.

ABSTRACT:

Background

Only a minority of melanoma patients experience durable responses to immunotherapies due to inter- and intra-tumoral heterogeneity in melanoma. As a result, there is a pressing need for suitable preclinical models to investigate resistance mechanisms and enhance treatment efficacy.

Methods

Here, we report two different methods for generating melanoma patient-derived organoids (MPDOs), one is embedded in collagen gel, and the other is inlaid in Matrigel. MPDOs in Matrigel are used for assessing the therapeutic effects of anti-PD-1 antibodies (αPD-1), autochthonous tumor infiltrating lymphocytes (TILs), and small molecule compounds. MPDOs in collagen gel are used for evaluating the chemotaxis and migratory capacity of TILs.

Finding

The MPDOs in collagen gel a

SUBMITTER: Ou L 

PROVIDER: S-EPMC10277922 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature